Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects
Status:
NOT_YET_RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label, sequential drug interaction study
The primary objectives are:
To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.